Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotorasib + panitumumab + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is an experimental regimen being evaluated in the Phase II COLOSOTO (ENGIC 01) clinical trial, sponsored by the Federation Francophone de Cancerologie Digestive (FFCD). It consists of sotorasib (a small molecule KRAS G12C inhibitor), panitumumab (a monoclonal antibody targeting EGFR), and 5-fluorouracil (a pyrimidine analog chemotherapy). The regimen is specifically designed as a first-line treatment for frail or elderly patients (aged 75+ or with a WHO performance status of 2) who have advanced unresectable colorectal adenocarcinoma harboring the KRAS G12C mutation and are ineligible for standard intensive doublet or triplet chemotherapy. By combining targeted inhibition of the KRAS G12C mutation and the EGFR pathway with low-intensity chemotherapy, the treatment aims to overcome resistance mechanisms and provide a tolerable yet effective option for this specific patient population.
- Brand names
- Lumakras + Vectibix + 5-fluorouracil
- Other names
- Sotorasib + Panitumumab + 5-FUSotorasib + Panitumumab + LV5FU2
02
Targets
TS (Thymidylate synthase)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on sotorasib + panitumumab + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotorasib + panitumumab + 5-fluorouracil.